Johnson & Johnson presents clinical data from a Phase 1b trial of a dual CD19/CD20-targeted CAR-T therapy for relapsed or refractory large B-cell lymphoma. High objective and complete response rates were observed, particularly in patients with fewer prior treatments, signaling a potential advance in addressing limitations of current single-target CAR-T therapies.